Published in N Engl J Med on April 25, 2013
GutHeart: Targeting Gut Microbiota to Treat Heart Failure | NCT02637167
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY) (GRADY) | NCT02016430
A Trial of the Ideal Protein System Versus Low Fat Diet for Weight Loss (RENEWAL) | NCT03515889
Choline Source, Gut Microbiota and Trimethylamine-N-oxide Response | NCT04255368
Analysis of MicroBial Metabolites After Eating Refined Food (AMBER) | NCT04308473
Plant-Based Meat vs Animal "Red" Meat Trial (FOOD-1) | NCT04510324
Facilitated Vegan Diet on Cardiometabolic Endpoints and Trimethylamine N-oxide | NCT05071196
Persistent gut microbiota immaturity in malnourished Bangladeshi children. Nature (2014) 4.00
Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis. Cell (2015) 2.77
Roux-en-Y Gastric Bypass and Vertical Banded Gastroplasty Induce Long-Term Changes on the Human Gut Microbiome Contributing to Fat Mass Regulation. Cell Metab (2015) 2.65
Gut Microbial Metabolite TMAO Enhances Platelet Hyperreactivity and Thrombosis Risk. Cell (2016) 2.64
Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol (2014) 2.48
Systemic effects of inflammation on health during chronic HIV infection. Immunity (2013) 2.34
γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. Cell Metab (2014) 2.20
Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J (2014) 2.08
Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res (2014) 2.02
Interactions between the intestinal microbiome and liver diseases. Gastroenterology (2014) 1.92
The gut microbiota and host health: a new clinical frontier. Gut (2015) 1.91
Consumption of spicy foods and total and cause specific mortality: population based cohort study. BMJ (2015) 1.88
Assessing the human gut microbiota in metabolic diseases. Diabetes (2013) 1.64
The contributory role of gut microbiota in cardiovascular disease. J Clin Invest (2014) 1.57
An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. Mucosal Immunol (2014) 1.54
Transmission of atherosclerosis susceptibility with gut microbial transplantation. J Biol Chem (2014) 1.53
Gallstone Disease and the Risk of Ischemic Heart Disease. Arterioscler Thromb Vasc Biol (2015) 1.49
Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation (2013) 1.48
Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms. PLoS One (2015) 1.48
Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook. Gastroenterology (2015) 1.42
Intestinal Dysbiosis, Barrier Dysfunction, and Bacterial Translocation Account for CKD-Related Systemic Inflammation. J Am Soc Nephrol (2016) 1.42
The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance. Cell Rep (2015) 1.40
Major Increase in Microbiota-Dependent Proatherogenic Metabolite TMAO One Year After Bariatric Surgery. Metab Syndr Relat Disord (2016) 1.40
Gut dysbiosis is associated with metabolism and systemic inflammation in patients with ischemic stroke. PLoS One (2017) 1.40
Vancomycin treatment and butyrate supplementation modulate gut microbe composition and severity of neointimal hyperplasia after arterial injury. Physiol Rep (2015) 1.38
Measurement of trimethylamine-N-oxide by stable isotope dilution liquid chromatography tandem mass spectrometry. Anal Biochem (2014) 1.37
Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. J Clin Invest (2014) 1.33
The gut microbiome in health and in disease. Curr Opin Gastroenterol (2015) 1.33
Diet and the intestinal microbiome: associations, functions, and implications for health and disease. Gastroenterology (2014) 1.33
The gut microbial endocrine organ: bacterially derived signals driving cardiometabolic diseases. Annu Rev Med (2015) 1.33
Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis. Nat Commun (2015) 1.32
Diet-microbiota interactions as moderators of human metabolism. Nature (2016) 1.31
Gut dysbiosis is linked to hypertension. Hypertension (2015) 1.28
The blood exposome and its role in discovering causes of disease. Environ Health Perspect (2014) 1.27
Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res (2014) 1.27
Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. MBio (2015) 1.26
Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation (2015) 1.25
Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J Card Fail (2014) 1.24
The microbiota-gut-brain axis: neurobehavioral correlates, health and sociality. Front Integr Neurosci (2013) 1.17
A Whole-Food Plant-Based Diet Reversed Angina without Medications or Procedures. Case Rep Cardiol (2015) 1.16
Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. J Am Soc Nephrol (2015) 1.15
A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. J Am Heart Assoc (2013) 1.15
Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol (2016) 1.14
Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc Natl Acad Sci U S A (2014) 1.13
Does the microbiome play a causal role in spondyloarthritis? Clin Rheumatol (2014) 1.12
Effect of egg ingestion on trimethylamine-N-oxide production in humans: a randomized, controlled, dose-response study. Am J Clin Nutr (2014) 1.10
The Gut Microbiome Contributes to a Substantial Proportion of the Variation in Blood Lipids. Circ Res (2015) 1.08
Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler Thromb Vasc Biol (2014) 1.08
The gut microbiome and the brain. J Med Food (2014) 1.06
Trimethylamine N-Oxide Promotes Vascular Inflammation Through Signaling of Mitogen-Activated Protein Kinase and Nuclear Factor-κB. J Am Heart Assoc (2016) 1.06
Archaebiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease. Gut Microbes (2013) 1.05
Microbial metabolism of dietary components to bioactive metabolites: opportunities for new therapeutic interventions. Genome Med (2016) 1.05
Archaea and the human gut: new beginning of an old story. World J Gastroenterol (2014) 1.04
Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J Lipid Res (2013) 1.03
Credentialing features: a platform to benchmark and optimize untargeted metabolomic methods. Anal Chem (2014) 1.03
Metaorganismal nutrient metabolism as a basis of cardiovascular disease. Curr Opin Lipidol (2014) 1.02
Gut microbiota, the genome, and diet in atherogenesis. N Engl J Med (2013) 1.01
Gut Microbiota Linked to Sexual Preference and HIV Infection. EBioMedicine (2016) 1.01
The dormant blood microbiome in chronic, inflammatory diseases. FEMS Microbiol Rev (2015) 0.99
Choline Diet and Its Gut Microbe-Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload-Induced Heart Failure. Circ Heart Fail (2015) 0.99
The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nat Rev Nephrol (2015) 0.98
Role of the enteric microbiota in intestinal homeostasis and inflammation. Free Radic Biol Med (2013) 0.98
The role of T and B cells in human atherosclerosis and atherothrombosis. Clin Exp Immunol (2015) 0.98
Fecal microbiota transplantation broadening its application beyond intestinal disorders. World J Gastroenterol (2015) 0.96
Associations of Trimethylamine N-Oxide With Nutritional and Inflammatory Biomarkers and Cardiovascular Outcomes in Patients New to Dialysis. J Ren Nutr (2015) 0.96
Marine fish may be biochemically constrained from inhabiting the deepest ocean depths. Proc Natl Acad Sci U S A (2014) 0.96
Zebrafish models of dyslipidemia: relevance to atherosclerosis and angiogenesis. Transl Res (2013) 0.95
Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest (2014) 0.95
Lung microbiome for clinicians. New discoveries about bugs in healthy and diseased lungs. Ann Am Thorac Soc (2014) 0.95
Antibiotic-Induced Changes in the Intestinal Microbiota and Disease. Trends Mol Med (2016) 0.94
Molecular Basis of C-N Bond Cleavage by the Glycyl Radical Enzyme Choline Trimethylamine-Lyase. Cell Chem Biol (2016) 0.94
Microbiome-wide association studies link dynamic microbial consortia to disease. Nature (2016) 0.93
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol (2016) 0.93
Characterization and detection of a widely distributed gene cluster that predicts anaerobic choline utilization by human gut bacteria. MBio (2015) 0.92
Anatomical localization of commensal bacteria in immune cell homeostasis and disease. Immunol Rev (2014) 0.92
A new model of reverse cholesterol transport: enTICEing strategies to stimulate intestinal cholesterol excretion. Trends Pharmacol Sci (2015) 0.91
Effect of renal impairment on atherosclerosis: only partially mediated by homocysteine. Nephrol Dial Transplant (2015) 0.91
Plasma Trimethylamine N-Oxide, a Gut Microbe-Generated Phosphatidylcholine Metabolite, Is Associated With Atherosclerotic Burden. J Am Coll Cardiol (2016) 0.91
A genome-wide systems analysis reveals strong link between colorectal cancer and trimethylamine N-oxide (TMAO), a gut microbial metabolite of dietary meat and fat. BMC Genomics (2015) 0.90
Metabolomics and diabetes: analytical and computational approaches. Diabetes (2015) 0.90
Role of gut microbiota in atherosclerosis. Nat Rev Cardiol (2016) 0.90
Metabolite Profiles of Diabetes Incidence and Intervention Response in the Diabetes Prevention Program. Diabetes (2016) 0.89
Meat-metabolizing bacteria in atherosclerosis. Nat Med (2013) 0.89
Choline supplementation in children with fetal alcohol spectrum disorders: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr (2015) 0.89
Intersections Between Microbiome and Heart Failure: Revisiting the Gut Hypothesis. J Card Fail (2015) 0.88
The genetic basis of peripheral arterial disease: current knowledge, challenges, and future directions. Circ Res (2015) 0.88
Microbial translocation and cardiometabolic risk factors in HIV infection. AIDS Res Hum Retroviruses (2014) 0.88
Far from the eyes, close to the heart: dysbiosis of gut microbiota and cardiovascular consequences. Curr Cardiol Rep (2014) 0.88
Commensal Microbe-specific Activation of B2 Cell Subsets Contributes to Atherosclerosis Development Independently of Lipid Metabolism. EBioMedicine (2016) 0.88
Human experimental endotoxemia in modeling the pathophysiology, genomics, and therapeutics of innate immunity in complex cardiometabolic diseases. Arterioscler Thromb Vasc Biol (2014) 0.88
Unraveling the environmental and genetic interactions in atherosclerosis: Central role of the gut microbiota. Atherosclerosis (2015) 0.88
Probiotics and Prebiotics: Present Status and Future Perspectives on Metabolic Disorders. Nutrients (2016) 0.87
Systems Epidemiology: A New Direction in Nutrition and Metabolic Disease Research. Curr Nutr Rep (2013) 0.87
Ischemic heart disease in women: a focus on risk factors. Trends Cardiovasc Med (2014) 0.87
Modulation of gut microbiota in the management of metabolic disorders: the prospects and challenges. Int J Mol Sci (2014) 0.87
In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I. J Lipid Res (2014) 0.87
Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease. PLoS One (2016) 0.86
The microbiota and microbiome in aging: potential implications in health and age-related diseases. J Am Geriatr Soc (2015) 0.86
The microbiota, chemical symbiosis, and human disease. J Mol Biol (2014) 0.86
Metagenomic analysis of the human distal gut microbiome. Science (2006) 29.76
The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A (2004) 26.56
Commensal host-bacterial relationships in the gut. Science (2001) 14.82
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature (2011) 13.53
Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature (2008) 12.45
Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med (2011) 10.03
Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A (2006) 5.19
Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med (2005) 4.13
Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology (2010) 3.68
Azithromycin for the secondary prevention of coronary events. N Engl J Med (2005) 3.42
Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab (2013) 3.01
Choline: critical role during fetal development and dietary requirements in adults. Annu Rev Nutr (2006) 2.83
Probiotic modulation of symbiotic gut microbial-host metabolic interactions in a humanized microbiome mouse model. Mol Syst Biol (2008) 2.43
Urinary excretion of choline metabolites following choline administration in normals and patients with hepatobiliary diseases. J Clin Invest (1951) 1.97
Susceptibility of human metabolic phenotypes to dietary modulation. J Proteome Res (2006) 1.96
Dietary precursors of trimethylamine in man: a pilot study. Food Chem Toxicol (1999) 1.90
Isoform specificity of trimethylamine N-oxygenation by human flavin-containing monooxygenase (FMO) and P450 enzymes: selective catalysis by FMO3. Biochem Pharmacol (1998) 1.80
The exogenous origin of trimethylamine in the mouse. Metabolism (1992) 1.78
Degradation of various amine compounds by mesophilic clostridia. Arch Microbiol (1986) 1.41
Trimethylamine: metabolic, pharmacokinetic and safety aspects. Curr Drug Metab (2005) 1.40
Trimethylamine oxide, betaine and other osmolytes in deep-sea animals: depth trends and effects on enzymes under hydrostatic pressure. Cell Mol Biol (Noisy-le-grand) (2004) 1.21
Amine metabolism and the small bowel in uraemia. Lancet (1976) 1.20
Lipid metabolism by gut microbes and atherosclerosis. Circ Res (2011) 1.18
Determination of body burden of uremic toxins. Clin Nephrol (1984) 1.07
The relative importance of N-oxidation and N-demethylation in the metabolism of trimethylamine in man. Toxicology (1987) 1.02
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature (2011) 13.53
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med (2013) 9.44
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA (2005) 6.14
Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med (2003) 5.89
Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med (2007) 4.30
Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med (2007) 4.11
Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet (2010) 3.97
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA (2008) 3.64
Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest (2004) 3.63
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA (2007) 3.25
A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions. J Biol Chem (2002) 3.17
New gene functions in megakaryopoiesis and platelet formation. Nature (2011) 3.14
Genome-wide association study of coronary heart disease and its risk factors in 8,090 African Americans: the NHLBI CARe Project. PLoS Genet (2011) 3.07
Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol (2013) 3.07
A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab (2006) 3.06
RhoA and microtubule dynamics control cell-basement membrane interaction in EMT during gastrulation. Nat Cell Biol (2008) 3.04
Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab (2013) 3.01
Identification of a novel family of oxidized phospholipids that serve as ligands for the macrophage scavenger receptor CD36. J Biol Chem (2002) 2.94
Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation (2004) 2.79
Myeloperoxidase and cardiovascular disease. Arterioscler Thromb Vasc Biol (2005) 2.77
Seventy-five genetic loci influencing the human red blood cell. Nature (2012) 2.77
Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J Exp Med (2006) 2.51
The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction. Nat Struct Mol Biol (2007) 2.47
Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J (2004) 2.37
Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk. J Am Coll Cardiol (2009) 2.35
The lipid whisker model of the structure of oxidized cell membranes. J Biol Chem (2007) 2.31
Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. Diabetes (2013) 2.25
Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol (2007) 2.22
Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study. Arthritis Rheum (2008) 2.19
Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA (2003) 2.16
Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J (2014) 2.08
Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem (2002) 2.02
Oxidative and nitrosative events in asthma. Free Radic Biol Med (2003) 1.97
p53 is a suppressor of inflammatory response in mice. FASEB J (2005) 1.91
Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J (2008) 1.88
Association between four SNPs on chromosome 9p21 and myocardial infarction is replicated in an Italian population. J Hum Genet (2007) 1.87
Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol (2006) 1.87
Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J (2008) 1.85
An association between L-arginine/asymmetric dimethyl arginine balance, obesity, and the age of asthma onset phenotype. Am J Respir Crit Care Med (2012) 1.85
Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction. Circulation (2007) 1.85
Coronary artery calcification and changes in atheroma burden in response to established medical therapies. J Am Coll Cardiol (2006) 1.84
Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem (2004) 1.80
An aqueous rechargeable lithium battery with good cycling performance. Angew Chem Int Ed Engl (2007) 1.77
Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clin Chem (2010) 1.74
Correlation of systemic superoxide dismutase deficiency to airflow obstruction in asthma. Am J Respir Crit Care Med (2005) 1.72
High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol (2012) 1.70
Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol (2005) 1.69
Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation (2003) 1.69
Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1. J Am Coll Cardiol (2012) 1.69
Myeloperoxidase deficiency enhances inflammation after allogeneic marrow transplantation. Am J Physiol Lung Cell Mol Physiol (2004) 1.68
Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2014) 1.66
Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure. J Am Coll Cardiol (2007) 1.66
Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med (2003) 1.59
The contributory role of gut microbiota in cardiovascular disease. J Clin Invest (2014) 1.57
Superoxide dismutase inactivation in pathophysiology of asthmatic airway remodeling and reactivity. Am J Pathol (2005) 1.56
Identification of alpha-chloro fatty aldehydes and unsaturated lysophosphatidylcholine molecular species in human atherosclerotic lesions. Circulation (2003) 1.55
Association of a genetic risk score with prevalent and incident myocardial infarction in subjects undergoing coronary angiography. Circ Cardiovasc Genet (2012) 1.54
Mass spectrometric profiling of oxidized lipid products in human nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Lipid Res (2010) 1.53
Antagonistic roles of Wnt5 and the Drl receptor in patterning the Drosophila antennal lobe. Nat Neurosci (2007) 1.53
Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem (2009) 1.51
Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med (2010) 1.49
An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarction. Am J Hum Genet (2007) 1.48
Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med (2005) 1.47
Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol (2003) 1.46
Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis (2006) 1.44
Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb Vasc Biol (2009) 1.44
Immunoglobulins against tyrosine-nitrated epitopes in coronary artery disease. Circulation (2012) 1.42